Mizuho Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)

September 20, 2024 6:46 AM EDT Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $20.00 price target on Adverum Biotechnologies (NASDAQ: ADVM).The analyst commented: "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login